CUROSURF

(Poractant alfa)

ApprovedSmall molecule

CUROSURF is one of 75 small molecule programs targeting Adult Acute Respiratory Distress Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Respiratory Distress SyndromeActive, not recruiting

Bronchopulmonary DysplasiaActive, not recruiting

HemorrhageActive, not recruiting

Adult Acute Respiratory Distress SyndromePhase 2

Active, not recruiting

Bronchopulmonary DysplasiaApproved

Active, not recruiting

HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

137 competitors in Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Phase 3

3 2

Cyklokapron

AAmring

Phase 3

10 3

Activase

Roche

Phase 3

1 4

CUROSURF

Chiesi Farmaceutici S.p.A.

Approved

1 5

Indocin

LLife Extension Foundation Inc.

Phase 3

1 6

Zocor

OOrganon and Co

Phase 3

1 7

Glypressin

MMallinckrodt

Phase 3

1 8

Betadine

BBecton, Dickinson and Company

Phase 3

1 9

Statins

Sanofi

Phase 3

1 10

Ulipristal Acetate

AbbVie

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Respiratory Distress Syndrome

NCT07350018

Q3 2027

Post-ApprovalRecruiting

Acute Lymphoblastic Leukemia

NCT06007547

Clinical

Trials by Indication[1]

Respiratory Distress Syndrome3 trials

Perfusion Index Variability in Respiratory Distress Syndrome

Completed·—·N/A·NCT01852461·92 enrolled

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

Completed·UUniversity of Missouri-Columbia·N/A·NCT02834624·30 enrolled

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

Not yet recruiting·UUludag University·Phase 4·NCT07350018·234 enrolled

Hemorrhage1 trial

Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage

Completed·—·N/A·NCT01860014·20 enrolled

Acute Lymphoblastic Leukemia1 trial

Prophylactic Minimally Invasive Surfactant Evaluation

Recruiting·EEndeavor Health·Phase 4·NCT06007547·200 enrolled

Respiratory Distress Syndrome (RDS)1 trial

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT02452476·123 enrolled

Adult Acute Respiratory Distress Syndrome1 trial

Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19

Unknown status·DDr Christophe LENCLUD·Phase 2·NCT04384731·20 enrolled

2 more indications

Bronchopulmonary Dysplasia1 trial

Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.

Unknown status·HHospital Central "Dr. Ignacio Morones Prieto"·Phase 4·NCT03521063·108 enrolled

Efficacy1 trial

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 4·NCT00501982·208 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 18, 1999

CUROSURF

BLA BLA020744

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Poractant alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Poractant alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Poractant alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA020744). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Chiesi Farmaceutici S.p.A.

CUROSURF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Respiratory Distress Syndrome3 trials

Hemorrhage1 trial

Acute Lymphoblastic Leukemia1 trial

Respiratory Distress Syndrome (RDS)1 trial

Adult Acute Respiratory Distress Syndrome1 trial

Bronchopulmonary Dysplasia1 trial

Efficacy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News